Primary Gastric Lymphoma Epidemiology Forecast 2025-2034

Primary Gastric Lymphoma Epidemiology Forecast Report Coverage

Expert Market Research's “Primary Gastric Lymphoma Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of primary gastric lymphoma. It projects the future incidence and prevalence rates of primary gastric lymphoma across various populations. The study covers age, gender, and type as major determinants of the primary gastric lymphoma-affected population. The report highlights patterns in the prevalence of Primary Gastric Lymphoma over time and projects future trends based on multiple variables.

Primary Gastric Lymphoma: Disease Overview

Primary gastric lymphoma is a rare kind of non-Hodgkin lymphoma that starts in the lymphoid tissue of the stomach. It is closely linked to Helicobacter pylori infection, which can cause chronic inflammation and lymphoid proliferation, and it makes up less than 5% of all gastric cancers. The symptoms of the condition (which mainly affects older adults) include nausea, gastrointestinal bleeding, weight loss, and abdominal pain. Usually, endoscopy, biopsy, and imaging tests like CT or PET scans are used to confirm the diagnosis.

Primary Gastric Lymphoma: Treatment Overview

The treatment of primary gastric lymphoma (PGL) is contingent upon the patient's condition, stage, and lymphoma subtype. Antibiotic therapy is frequently used as the first line of treatment for Helicobacter pylori-associated mucosa-associated lymphoid tissue (MALT) lymphoma to eradicate H. pylori, which frequently results in remission. Diffuse large B-cell lymphoma (DLBCL) and other advanced or high-grade lymphomas usually require chemotherapy (such as the R-CHOP regimen) in addition to or instead of radiation therapy. Targeted treatments, like rituximab, may be used in certain situations. Except in cases of bleeding or perforation, surgery is rarely required.

Epidemiology

The primary gastric lymphoma epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for primary gastric lymphoma by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for primary gastric lymphoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• About 30% to 40% of all extranodal lymphomas and 4% of gastrointestinal tumors were primary gastrointestinal lymphomas. The entire digestive tract may be affected by PGIL, but the stomach is the most frequently affected area (60–75%), followed by the small intestine (20–30%), large intestine (5%–10%), and esophagus (<1%).
• Some studies addressed that although patients over 50 are more likely to experience primary gastric lymphoma, those in their second decade of life may also be impacted. Compared to women, men are two to three times more likely to develop the condition.
• A study indicates that the early symptoms of the disease are typically vague and can resemble pancreatic disorders, peptic ulcer disease, gastritis, or stomach functional disorders. In 55% to 60% of cases, the physical examination is unremarkable. Hematemesis or melena, a type of gastrointestinal bleeding, is reported by 20% to 30% of patients with gastric DLBCL.
• A study has revealed that studies on chemotherapy, surgery, and their combination have shown nearly identical outcomes in primary gastric lymphoma, with survival rates ranging from 70% to 90%. It was addressed that chemotherapy does have the benefit of protecting the stomach structure. However, the use of radiotherapy alone has been tested and proven to be effective.

Country-wise Primary Gastric Lymphoma Epidemiology

The primary gastric lymphoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of primary gastric lymphoma varies between countries owing to the differences in factors such as poor dietary habits, alcohol and tobacco smoking, weakened immune system, chronic gastritis and autoimmune disorders and others. Non-Hodgkin lymphoma (NHL) which is a term that includes a variety of neoplasms of lymphoid origin is the most prevalent kind of blood cancer in the United States. About 30–40% of all NHL cases are extranodal non-Hodgkin lymphoma (EN-NHL), which most frequently occurs in the gastrointestinal tract. About 2% of all gastrointestinal cancers are primary intestinal non-Hodgkin lymphoma (PI-NHL), which accounts for 0.2% of all large intestinal cancers and 2% of all small intestinal cancers.

Country Specific Stats:

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Primary Gastric Lymphoma based on several factors.
• Primary Gastric Lymphoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Primary Gastric Lymphoma are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of primary gastric lymphoma epidemiology in the 8 major markets?
• What will be the total number of patients with primary gastric lymphoma across the 8 major markets during the forecast period?
• What was the country-wise prevalence of primary gastric lymphoma in the 8 major markets in the historical period?
• Which country will have the highest number of primary gastric lymphoma patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of primary gastric lymphoma during the forecast period of 2025-2034?
• What are the currently available treatments for primary gastric lymphoma?
• What are the disease risks, signs, symptoms, and unmet needs of primary gastric lymphoma?

Related Reports

Gastric Ulcer Treatment Market

Global Hodgkin’s Lymphoma Treatment Market